Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study
In this prospective study (N = 12), autologous virus-specific T cells (auto-VSTs) were successfully manufactured in 10 patients (83.3%). Three received VSTs, achieving viral clearance and symptom resolution without severe adverse events. Auto-VST therapy appears feasible and effective for managing persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, manufacturing and timing challenges remain.
Authors
- Dukhee Nho (ORCID: https://orcid.org/0000-0003-2800-636X)
- Raeseok Lee (ORCID: https://orcid.org/0000-0002-1168-3666)
- Chulmin Park (ORCID: https://orcid.org/0000-0001-9147-0478)
- I.-Jung Lee
- Seok‐Goo Cho (ORCID: https://orcid.org/0000-0002-5429-4839)
- Won-Bok Kim (ORCID: https://orcid.org/0000-0002-9111-0365)
- Nayoun Kim (ORCID: https://orcid.org/0000-0001-8317-2921)
- Dong‐Gun Lee (ORCID: https://orcid.org/0000-0003-4655-0641)
- Sung‐Yeon Cho (ORCID: https://orcid.org/0000-0001-5392-3405)
- Keon-Il Im (ORCID: https://orcid.org/0000-0003-2811-9815)
- Kyongmin Sarah Beck (ORCID: https://orcid.org/0000-0002-9262-1001)
- GyeongHui Lee
Institutions
- Lucas Research (US)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-06-08
- DOI
- https://doi.org/10.1093/cid/ciaf302
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Korea Health Industry Development Institute